focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.75
Bid: 1.70
Ask: 1.80
Change: 0.10 (6.06%)
Spread: 0.10 (5.882%)
Open: 1.65
High: 1.95
Low: 1.65
Prev. Close: 1.65
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: iEnergizer to depart; Unbound for sale

Fri, 19th May 2023 10:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

iEnergizer PLC, up 24% at 67 pence, 12-month range 29.5p-526p. The Noida, India-based IT service management firm says its shares will stop trading on AIM on Wednesday. In April, it said it was seeking cancellation, stating that staying on the stock exchange was "unlikely to provide the company with significantly wider access to capital", adding that the cost and legal implications of maintaining its admission to trading on AIM were "disproportionate" to the benefits.

----------

Genedrive PLC, up 16% at 23.70p, 12-month range 8.00p-48.86p. The point-of-care molecular diagnostics firm says the UK National Institute for Health & Care Excellence recommends in draft guidance that CYP2C19 genotyping should be used before clopidogrel administration in managing ischemic stroke patients. "Screening patients to assess their clopidogrel resistance status allows for alternative treatments and better clinical outcomes," the company explains. The NICE Committee included the firm's CYP2C19 ID test in its review. Genedrive notes the test is still in development. Awaits the UKCA marking on the test prior to NICE's final report, currently scheduled for October.

----------

AIM - LOSERS

----------

Velocys PLC, down 28% at 2.41p, 12-month range 2.20p-7.30p. The sustainable fuels technology company says the books are covered at around GBP6 million for its placing and retail offer. The books remain open. The fundraise was announced after the market close on Thursday, with an issue price of 2.5p for each. The price is a 26% discount to Thursday's closing price of 3.4p. Velocys had voiced concerns over its ability to continue as a going concern. It aims to raise at least GBP32 million by the placing, retail offer, open offer, as well as a conditional issuance of convertible loan notes to Carbon Direct Capital and potential further issuances of convertible loan notes and/or new ordinary shares to investors other than Carbon Direct Capital.

----------

Unbound Group PLC, down 23% at 2.51p, 12-month range 2.51p-35.94p. The stock reaches a 12-month low as the firm launches a strategic review, including a formal sales process. Unbound is the parent company for a retail group selling a range of brands focused on the 55+ demographic, including Hotter Shoes. The review is to explore its strategic options, and could include a full sale of the company. Unbound warns a temporary working capital shortfall could arise in September and October this year. It continues to work with its advisers and banking partners to raise additional funds or refinance its current facilities.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Apr 2020 11:40

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Genedrive To Collaborate On Rapidly Manufactured Covid-19 Test

Read more
25 Mar 2020 14:57

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Genedrive Shares Soar As It Says It Will Develop SARS-COV-2 Tests

Read more
4 Feb 2020 12:22

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Genedrive Shares Plunge 45% As Loss Widens On Shipping Order Delays

Read more
28 Jan 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Dec 2019 10:10

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Read more
3 Dec 2019 09:39

Genedrive upbeat on latest results from RNR1 kit testing

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Tuesday that in its case-control clinical validation, the antibiotic-induced hearing loss assay - the 'Genedrive MT-RNR1 ID' kit - achieved a diagnostic sensitivity of 100% and specificity of 100% on a cohort of 303 samples.

Read more
18 Nov 2019 16:00

Genedrive infant hearing loss test gets CE mark

(Sharecast News) - Molecular diagnostics company Genedrive announced on Monday that its antibiotic-induced hearing loss test, the 'Genedrive MT-RNR1 ID' kit, has obtained CE marking.

Read more
18 Nov 2019 11:15

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Read more
7 Oct 2019 11:59

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

Read more
3 Oct 2019 11:00

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Read more
3 Oct 2019 10:41

Genedrive loss narrowed after double-digit revenue rise

(Sharecast News) - Genedrive on Thursday reported a narrowed annual loss as revenues jumped as its commercial relationship with the US department of defense (DoD) exceeded expectations.

Read more
9 Jul 2019 10:54

Genedrive Revenue To Suffer On Lower Uptake Of Hepatitis Test Kits

(Alliance News) - Shares in Genedrive PLC fell Tuesday after the company warned that it will miss market expectations for 2020 financial year revenue due to slower than expected uptake of the HCV

Read more
28 Mar 2019 10:36

Genedrive Interim Loss Narrows As It Continues Focus On Hepatitis

LONDON (Alliance News) - Genedrive PLC on Thursday reported a reduction in its interim loss, as it continues to progress its hepatitis testing product.For the six months to the end of 2018,

Read more
28 Mar 2019 07:59

Genedrive losses narrow despite increased R&D costs

(Sharecast News) - Molecular diagnostics company Genedrive saw revenues tick ahead slightly in the first half of its financial year but increased research and development costs kept the firm in the red.

Read more
15 Jan 2019 12:44

Genedrive Interim Revenue Rises On US And UK Government Contracts

LONDON (Alliance News) - Genedrive PLC said Tuesday it increased its first-half income and made "good progress" on two UK government funded projects.For the six months to the end

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.